RE:NO insider selling and "with this sample size"I don't understand why the phrase "with this sample size" was repeated twice in the recent news release.
The company and the FDA clearly stated the primary end point would be done on the final 176 patients, the last of the 446. I do realize this number was extended to 180 as part of the eventual 450.
As much as we appreciate the 5% on "this sample size", what was the absolute benefit on the number of 176/180 as set by the FDA?
I have many questions and will reach out to the company for answers.
I've always known that games were being played here, they've become "downright dirty" and now our friends in the US have finally discovered the EDTXF ticker symbol and LONG or BUY button
Sqr
Read more at https://www.stockhouse.com/companies/bullboard#4PuA243kXuaexwMb.99